This company listing is no longer active
Ergomed (ERGO) Stock Overview
Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, rest of Europe, the Middle East, Africa, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ERGO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Ergomed plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£13.46 |
| 52 Week High | UK£13.80 |
| 52 Week Low | UK£8.95 |
| Beta | 0.79 |
| 1 Month Change | 0.90% |
| 3 Month Change | 21.26% |
| 1 Year Change | 3.54% |
| 3 Year Change | 67.41% |
| 5 Year Change | 812.54% |
| Change since IPO | 728.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| ERGO | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | 0.1% | -4.8% | 2.4% |
| 1Y | 3.5% | -1.7% | 18.2% |
Return vs Industry: ERGO exceeded the UK Life Sciences industry which returned -15.7% over the past year.
Return vs Market: ERGO exceeded the UK Market which returned -2.4% over the past year.
Price Volatility
| ERGO volatility | |
|---|---|
| ERGO Average Weekly Movement | 8.1% |
| Life Sciences Industry Average Movement | 8.3% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in GB Market | 11.2% |
| 10% least volatile stocks in GB Market | 3.1% |
Stable Share Price: ERGO's share price has been volatile over the past 3 months.
Volatility Over Time: ERGO's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 1,400 | n/a | www.ergomedplc.com |
Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, rest of Europe, the Middle East, Africa, North America, and internationally. The company operates through two segments, Clinical Research Services and Pharmacovigilance. It provides and manages clinical development, trial management, and pharmacovigilance services for pharmaceutical, biotechnology, and generics companies.
Ergomed plc Fundamentals Summary
| ERGO fundamental statistics | |
|---|---|
| Market cap | UK£701.05m |
| Earnings (TTM) | UK£15.00m |
| Revenue (TTM) | UK£152.09m |
Is ERGO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ERGO income statement (TTM) | |
|---|---|
| Revenue | UK£152.09m |
| Cost of Revenue | UK£68.82m |
| Gross Profit | UK£83.27m |
| Other Expenses | UK£68.27m |
| Earnings | UK£15.00m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.29 |
| Gross Margin | 54.75% |
| Net Profit Margin | 9.86% |
| Debt/Equity Ratio | 0% |
How did ERGO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/11/13 22:53 |
| End of Day Share Price | 2023/11/13 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ergomed plc is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Samuel England | Berenberg |
| Colin Grant | Davy |
| Jonas Peciulis | Edison Investment Research |